On-Demand Webinar | The Precision Bridge: MRI-Guided CED and Translatable NHP Models for CNS Drug Delivery
📅 Original Broadcast
Executive Summary
Accurate delivery of therapeutics to specific regions of the brain remains a central challenge in central nervous system (CNS) drug development. Limitations associated with the blood–brain barrier (BBB), as well as constraints in verifying target engagement, contribute to uncertainty during clinical translation.
This technical session introduces an integrated approach combining intraoperative MRI (iMRI)-guided navigation with Convection-Enhanced Delivery (CED) in non-human primate (NHP) models. This synergy enables real-time visualization and controlled intracranial administration, establishing a more predictable path for high-complexity therapeutics.
Key Technical Learning Objectives
Explore how consistency between preclinical and clinical workflows supports more informed decision-making in CNS drug development, focusing on:
- Target Verification: Addressing foundational challenges in CNS drug delivery and biodistribution.
- iMRI-Guided Procedures: Comparative insights into MRI-guided vs. MRI-verified intracranial methodologies.
- CED Principles: Mechanics and applications of Convection-Enhanced Delivery for optimizing brain parenchymal coverage.
- Precision Navigation: Integration of navigation systems for trajectory planning and real-time monitoring.
- Translational Continuity: Strategies for improving the transition of gene and cell therapies from preclinical stages to clinical trials.
Distinguished Speakers
David S. Wong
BD Manager, Asia Pacific, ClearPoint Neuro
David Wong has been with the Biologics & Drug Delivery Team at ClearPoint Neuro for 4 years, specializing in clinical trials and regulatory projects across Asia, Oceania, and North America. With a nearly 20-year career in medical devices and pharmaceuticals, he holds a Master's in Biotechnology from Johns Hopkins University.
James Song
General Manager, PRISYS Biotech
James Song leverages 20 years of expertise in NHP pharmacology and disease modeling. He specializes in navigating the complexities of translational medicine and has led the development of Prisys' sophisticated laboratory infrastructure and unique NHP models to bridge the gap between lab and clinic.
Access the Resource Center
Join global professionals in preclinical pharmacology, neuroscience, and gene therapy to gain a structured understanding of current approaches to CNS drug delivery.
Passcode: T09TK?Zb
Note: Registration is required to access the recording and technical Lite-version of the presentation deck.
Further Inquiry
To schedule a technical follow-up or discuss specific project requirements, please contact our team at:
Email: bd@prisysbiotech.com
FAQ
Q: What are the benefits of using iMRI-guided CED in CNS drug delivery?
A: iMRI-guided CED allows for real-time visualization of the infusion process, ensuring that the therapeutic reaches the exact target region in the brain while monitoring distribution and minimizing off-target effects.
Q: Why are NHP models critical for CNS drug translation?
A: Non-human primates (NHPs) possess brain structures and neuroanatomical features highly similar to humans, making them the gold standard for testing intracranial delivery systems and predicting clinical outcomes for gene and cell therapies.
Q: How does Convection-Enhanced Delivery (CED) differ from conventional injection?
A: Unlike simple diffusion, CED utilizes a pressure gradient to achieve uniform distribution of therapeutics across larger volumes of the brain parenchyma, overcoming the limitations of the blood-brain barrier.
